NRX Pharmaceuticals, Inc. (NRXP): Nasdaq/NYSE listing notice — NRX Pharmaceuticals receives Nasdaq delisting notice for bid price non-compliance; plans hearing

NRX Pharmaceuticals, Inc.

Received Nasdaq delisting notice Oct 17, 2023 for failing minimum bid price rule (closing bid <$1 for 30 days).
Plans to request hearing before Nasdaq Hearings Panel; hearing request will stay delisting pending decision.
Initial 180-day compliance period expired Oct 16, 2023 without regaining compliance.
Identifies four potential positive business developments that could affect share price, including NRX-101 trial data and milestone.
No assurance of Panel decision or ability to regain listing compliance within any extension.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

NRX Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

October 17, 2023, NRx Pharmaceuticals, Inc. (the “Company”) received formal notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”), the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which

View on SEC.gov

Browse all listing & compliance notices →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-110788

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.